WEE1抗体;WEE1 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P12877(WEE1 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P12877(WEE1 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

WEE1 is a serine/threonine kinase critical for cell cycle regulation, primarily acting at the G2/M checkpoint. It phosphorylates and inhibits cyclin-dependent kinase 1 (CDK1), delaying mitotic entry to allow DNA repair and maintain genomic stability. Dysregulation of WEE1 is implicated in cancer, as many tumors rely on its function to survive replication stress caused by oncogene activation or chemotherapy. Inhibiting WEE1 forces cancer cells with DNA damage to bypass the G2/M checkpoint, leading to mitotic catastrophe and apoptosis. This therapeutic vulnerability has driven interest in WEE1-targeted therapies, including small-molecule inhibitors like AZD1775.

WEE1 antibodies are essential tools for studying its expression, localization, and function in both normal and cancerous tissues. They enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Researchers use these antibodies to correlate WEE1 levels with patient prognosis, drug response, or genomic instability biomarkers. Specific antibody clones are validated for selective binding to human WEE1. though cross-reactivity with murine orthologs may vary. Recent studies also explore WEE1's role in combination therapies, particularly with DNA-damaging agents or PARP inhibitors, highlighting the antibody's utility in mechanistic and translational research.